Hepatitis B virus surface (S) transactivator with DNA-binding properties

Journal of Medical Virology

Volumn 61, Issue 1, 2000, Pages 1-10

  Alka, Saxena ^a   Hemlata, Durgapal ^a   Vaishali, Chaudhuri ^a   Shahid, Jameel ^b   Kumar, Panda Subrat ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

Cellular and viral promoters; Electrophoretic mobility shift assay; Hepatitis B virus; Hepatocellular carcinoma; Transactivator

Indexed keywords

TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DNA BINDING; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NONHUMAN; PROMOTER REGION; TRANSACTIVATION; VIRUS ACTIVATION;

AVIAN SARCOMA VIRUSES; CELL LINE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, VIRAL; GENES, FOS; GENES, JUN; HEPATITIS B VIRUS; HIV LONG TERMINAL REPEAT; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; TERMINAL REPEAT SEQUENCES; TRANS-ACTIVATORS;

DNA VIRUSES; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; ROUS SARCOMA VIRUS;

EID: 0034032052     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(200005)61:1<1::AID-JMV1>3.0.CO;2-A     Document Type: Article

References (36)

1. Angel P, Karin M. 1991. The role of jun, fos and the AP1 complex in cell proliferation and transformation. Biochem Biophys Acta 1072: 129-157.
2. Angel P, Hattori K, Smeal T, Karin M. 1988. The jun proto-oncogene is positively autoregulated by its product jun/AP-1. Cell 55:875-885.
3. Beasely RP, Hwang LY. 1984. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoffnagle JH, editors. Viral Hepatitis and Liver Disease. Florida: Gune and Stratton. p 275-305.
4. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. 1990. Abnormal structure and function of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 87:1973-1977.
5. Caselmann WH, Meyer M, Kekule AS, Lauer U, Hofschneider PH, Koshy R. 1990. A transactivator function is generated by integration of hepatitis B virus preSß sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci USA 87:2970-2974.
6. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD. 1989. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59:1145-1156.
7. Colgrove R, Simon G, Ganem D. 1989. Transcriptional activation of homologous and heterologous genes by hepatitis B virus X gene products in cells permissive for viral replication. J Virol 63:4019-4026.
8. Delgeschlager T, Chiang CM, Roeder RG. 1996. Topology and reorganisation of a human TFIID-promoter complex. Nature 382:735-738.
9. Deschamps J, Meijlink F, Verma IM. 1985. Identification of a transcriptional enhancer element upstream from the proto-oncogene fos. Science 230:1174-1177.
10. de The H, Marchio A, Tiollais P, Dejan A. 1987. A novel steroid thyroid hormone receptor related gene inappropriately expressed in human hepatocellular carcinoma. Nature 330:667-670.
11. Flint J, Shenk T. 1989. Adenovirus Ela protein paradigm viral transactivator. Annu Rev Genet 23:141-161.
12. Gill G, Ptashne M. 1988. Negative effect of the transcriptional activator GAL4. Nature 334:721-724.
13. Gorman CM, Merlino GT, Willingham MC, Pastan I, Howard BH. 1982a. The rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA mediated transfection. Proc Natl Acad Sci USA 79:6777-6781.
14. Gorman CM, Moffatt LF, Howard BH. 1982b. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044-1051.
15. Himeno Y, Fukuda Y, Hatanaka M, Imura H. 1988. Expression of oncogenes in human liver disease. Liver 8:208-212.
16. Hino O, Kitagawa T, Sugano H. 1985. Relationship between serum and histochemical markers for hepatitis B virus and rate of viral integration in hepatocellular carcinomas in Japan. Int J Cancer 35:5-10.
17. Jameel S, Siddiqui A. 1986. The human hepatitis B virus enhancer requires transacting cellular factor(s) for activity. Mol Cell Biol 6:710-715.
18. Kim HS, Ryu CJ, Hong HJ. 1997. Hepatitis B virus pre S1 functions as a transcriptional activation domain. J Gen Virol 78:1083-1086.
19. Maguire HF, Hoeffler JP, Siddiqui A. 1991. HBV X protein alters the DNA binding specificity of CREB and ATF2 by protein-protein interactions. Science 252:842-844.
20. Major J. 1990. The structure and function of retroviral long terminal repeats. In: Swanstrom R, Vogt PK, editors. Retroviruses Strategies of Replication. New York: Springer-Verlag, p 49-92.
21. Natoli G, Avantaggiati ML, Chirillo P, Costanzo A, Artini M, Balsano C, Levrero M. 1994. Induction of DNA binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX. Mol Cell Biol 14:989-998.
22. Ramesh R, Panda SK, Jameel S, Rajsambandam P. 1994. Mapping of the HBV genome in hepatocellular carcinoma using PCR and demonstration of a potential trans-activator encoded by the frequently detected fragment. J Gen Virol 75:327-334.
23. Rossner MT. 1992. Review. Hepatitis B virus X-gene product: a promiscuous transcriptional transactivator. J Med Virol 36:101-117.
24. Seto E, Yen TSB, Peterlin BM, Ou JH. 1988. Transactivation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad USA 85:8286-8290.
25. Shih CC, Stoye JP, Coffin JM. 1988. Highly preferred targets for retrovirus integration. Cell 53:531-537.
26. Sodroski JG, Rosen CA, Haseltine WA. 1984. Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science 225:381-385.
27. Tabor F. 1994. Tumor suppressor genes, growth factor genes and oncogenes in hepatitis B virus associated hepatocellular carcinoma. J Med Virol 42:357-365.
28. Terradillos O, Billet O, Renard C-A, Levy R, Molina T, Briand P, Buendia MA. 1997. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 14: 395-404.
29. Twu JS, Lai MY, Chen DS, Robinson WS. 1993. Activation of protooncogene c-jun by the X protein of hepatitis B virus. Virology 192:346-350.
30. Twu JS, Schloemer RH. 1987. Trancriptional transactivating function of hepatitis B virus. J Virol 61:3448-3453.
31. Varmus HE. 1984. The molecular genetics of cellular oncogenes. Annu Rev Genet 18:553-612.
32. Wang J, Chenivesse X, Henglein B, Brechot C. 1990. Hepatitis B virus integration in a cyclin A gene in HCC. Nature 348:555-557.
33. Wei Y, Ponzetto A, Tiollais P, Buendia MA. 1992. Multiple rearrangements and activated expression of c-myc induced by woodchuck hepatitis virus integration in a primary liver tumor. Res Virol 143:89-96.
34. Yaginuma K, Kobayashi H, Kobayashi M, Matasuyama K, Koike K. 1987. Multiple integration site of hepatitis B viral DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children. J Virol 61:1808-1813.
35. Zahm P, Hofschneider PH, Koshy R. 1988. The HBV X ORF encodes a transactivator: a potential factor in viral hepatocarcinogenesis. Oncogene 3:169-177.
36. Zhou XD, Debolla L, Custer RP, London WT. 1987. Iron, ferretin hepatitis B surface and core antigens in the line of Chinese patients with hepatocellular carcinoma. Cancer 59:1430-1437.